Pavilion Publishing and Media Ltd
Blue Sky Offices Shoreham, 25 Cecil Pashley Way, Shoreham-by-Sea, West Sussex, BN43 5FF, UNITED KINGDOM
Tel: +44 (0)1273 434 943
Email: [email protected]
A new biosimilar for teriparatide (Terrosa) is now available in the UK for the treatment of osteoporosis in a subset of patients.
This decision means that the NHS can provide an additional option for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.
Teriparatide biosimilar is also indicated in men and women at increased risk of fracture whose osteoporosis is associated with sustained systemic glucocorticoid therapy. It has been shown to significantly reduce the risk of both vertebral and non-vertebral fractures, but not hip fractures, in postmenopausal women.
In clinical studies, teriparatide biosimilar has been shown to be therapeutically equivalent to its reference drug Forsteo.
Dr Kathrine Scott, Medical Director at Gedeon Richter UK, said: “The availability of teriparatide biosimilar offers an alternative treatment option to eligible patients with an increased risk of fractures. NHS England supports the appropriate use of the best value biological medicine which will drive greater competition to release cost efficiencies to support the treatment of an increasing number of patients with biological medicines and the uptake of new and innovative medicines. We are pleased that practitioners now have the option of prescribing this.”
Teriparatide biosimilar is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. It has been shown to significantly reduce the risk of both vertebral and non-vertebral fractures, but not hip fractures, in postmenopausal women. It is also indicated in men and women at increased risk of fracture whose osteoporosis is associated with sustained systemic glucocorticoid therapy.